Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02479698 · ClinicalTrials.gov registry record · Phase 2
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
A Phase 2 study of Malignant Neoplasm and Human Immunodeficiency Virus, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT02479698: Recruiting Phase 2 study of Malignant Neoplasm and Human Immunodeficiency Virus, sponsored by M.D. Anderson Cancer Center.
NCT02479698 is a Phase 2 study of Malignant Neoplasm and Human Immunodeficiency Virus that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02479698, a Phase 2 study of Malignant Neoplasm and Human Immunodeficiency Virus, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Primary Outcome
The method of Thall et al will be used to monitor the probabilities of response.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Allogeneic BK-specific Cytotoxic T-lymphocytes
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-07-23 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
What NCT02479698 shows while recruiting
NCT02479698 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower).
The record links to 8 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02479698 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02479698 about?
NCT02479698 is a clinical study titled "Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus". This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant ...
What is the current status of trial NCT02479698?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2015-07-23. Estimated completion is 2027-07-31.
What conditions does trial NCT02479698 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Human Immunodeficiency Virus, Merkel Cell Carcinoma, Acquired Immunodeficiency Syndrome, BK Virus Infection.
What interventions are being tested in trial NCT02479698?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Allogeneic BK-specific Cytotoxic T-lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02479698?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02479698 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02479698's enrollment target sits among peer trials
100 33rd of 59 higher than 25 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Dexamethasone in Controlling Dyspnea in Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI